Clinical Trial Update: Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating rifaximin for liver scarring in HIV-infected individuals with liver disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Douglas T. Dieterich | Conditions: HIV, Hepatitis C | Phase 4 | Status: WITHDRAWN